In vitro studies in drug discovery and development: An analysis of study objectives and application of good laboratory practices (GLP)

Drug Metabolism Reviews

Volumn 34, Issue 4, 2002, Pages 679-689

  Bajpai, Manoj ^a   Esmay, Joel D ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CIPROFLOXACIN; COMPLEMENTARY DNA; CYTOCHROME P450; DOXORUBICIN DERIVATIVE; GLYCOPROTEIN P; IODODEOXYDOXORUBICIN; ISOENZYME; LIGAND; METHADONE; N ACETYL 1,4 BENZOQUINONE IMINE; PACLITAXEL; PHENYTOIN; UNCLASSIFIED DRUG; VERAPAMIL;

ASSAY; AUTOMATION; BINDING ASSAY; CANCER CELL CULTURE; COLON CARCINOMA; CONFERENCE PAPER; CONFUSION; CROSS REACTION; CYTOMETRY; DECISION MAKING; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; EFFUSION; ENZYME BLOOD LEVEL; FEEDBACK SYSTEM; GOOD LABORATORY PRACTICE; HUMAN; INFORMATION; INHIBITION KINETICS; INTESTINE CELL; LABORATORY; LIVER CELL CULTURE; LIVER TOXICITY; MATERIALS HANDLING; MEMBRANE PERMEABILITY; METABOLITE; MONOLAYER CULTURE; NONHUMAN; PRACTICE GUIDELINE; RESPIRATION DEPRESSION; SAFETY; SEDATION; ANIMAL; DRUG SCREENING; METHODOLOGY; PHARMACEUTICS; REVIEW;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036445715     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120015690     Document Type: Conference Paper

References (52)

1. Yuan, R.; Parmelee, T.; Balian, J.D.; Uppoor, R.S.; Ajayi, F.; Burnett, A.; Lesko, L.J.; Marroum, P. Pharmacokinetics and drug disposition in vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin. Pharmacol. Ther. 1999, 66, 9-15.
2. Good Laboratory Practice For Nonclinical Studies, U.S. Code of Federal Regulations, Title 21, Part 58, April 1, 2000; Chap. I.
3. Pinto, M.; Robine-Leon, S.; Appay, M.-D.; Kedinger, M.; Triadou, N.; Dussaulx, E.; LaCroix, B.; Simon-Assmann, P.; Haffen, K.; Fogh, J.; Zweibaum, A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 1983, 47, 323-330.
4. Hidalgo, I.J.; Raub, T.J.; Borchardt, R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96, 736-749.
5. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175 (3), 880-885.
6. 3. Mol. Pharmacol. 1997, 51, 741.
7. Garberg, P.; Eriksson, P.; Schipper, N.; Sjöström, B. Automated absorption assessment using Caco-2 cells cultured on both sides of polycarbonate membranes. Pharm. Res. 1999, 16 (3), 441-445.
8. Taylor, E.W.; Gibbons, J.A.; Braeckman, R.A. Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model. Pharm. Res. 1997, 14 (5), 572-577.
9. McCarthy, S.; Osbourne, S.; Kuhfeld, M. Automated permeability analysis of mixtures across Caco-2 cell monolayers. Pharm. Res. 1996, 13 (9), S242.
10. Bu, H.Z.; Poglod, M.; Micetich, R.G.; Khan, J.K. High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 523-528.
11. Chong, S.; Dando, S.A.; Morrison, R.A. Evaluation of Biocoat© intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm. Res. 1997, 14 (12), 1835-1837.
12. Irvine, J.D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J.W.; Selick, H.E.; Grove, J.R. MDCK (Madin-Darby Canine Kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 1999, 88 (1), 28-33.
13. Yee, S.; Day, W.W. Applications of Caco-2 cells in drug discovery and development. In Handbook of Drug Metabolism; Woolf, T., Ed.; Marcel Dekker, Inc.: New York, 1999; Chap. 19, 507-522.
14. Hunter, J.; Jepson, M.A.; Tsuruo, T.; Simmons, N.L.; Hirst, B.H. Functional expression of P-Glycoprotein in apical membranes of human intestinal Caco-2 cells kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 1993, 268 (20), 14991-14997.
15. Anderle, P.; Niederer, E.; Rubas, W.; Hilgendorf, C.; Spahn-Langguth, H.; Wunderli-Allenspach, H.; Merkle, H.P.; Langguth, P. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 1998, 87 (6), 757-762.
16. Tiberghien, F.; Loor, F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 1996, 7, 568-578.
17. Emeroth, A.; Åström, E.; Hoogstraate, J.; Schrenk, D.; Conrad, S.; Kauffmann, H.-M.; Gjellan, K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein-AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 2001, 12, 205-214.
18. 3H]Verapamil radioligand-binding assay. J. Pharmacol. Exp. Ther. 1999, 288, 348-357.
19. Letrent, S.P.; Pollack, G.M.; Brouwer, K.R.; Brouwer, K.L.R. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 1999, 27 (7), 827-834.
20. Letrent, S.P.; Polli, J.; Humphreys, J.; Pollack, G.; Brouwer, K.R.; Brouwer, K.L. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 1999, 58, 951-957.
21. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; Maclntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 1997, 283 (1), 46-58.
22. Li, A.P.; Lu, C.; Brent, J.A.; Pham, C.; Fackett, A.; Reugg, C.E.; Silber, P.M. Cryopreserved human hepatocytes: Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem.-Biol. Interact. 1999, 121, 17-35.
23. Newton, D.J.; Wang, R.W.; Lu, A.Y.H. Cytochrome P450 inhibitors evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995, 23 (1), 154-158.
24. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro, Department of Heath and Human Services, U.S. F.D.A., Center for Drug Evaluation and Research, April 1997.
25. Wang, W.; Lu, A.Y.H. Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab. Dispos. 1997, 25 (6), 762-767.
26. Bajpai, M.; Roskos, L.K.; Shen, D.D.; Levy, R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 1996, 24 (12), 1401-1403.
27. Mullins, M.E.; Horowitz, B.Z.; Linden, D.H.J.; Smith, G.W.; Norton, R.L.; Stump, J. Life-threatening interaction of mibefradil and P-blockers with dihydropyridine calcium channel blockers. J. Am. Med. Assoc. 1998, 280 (2), 157-158.
28. Wandel, C.; Kim, R.B.; Guenerich, F.P.; Wood, A.J.J. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 2000, 28 (8), 895-898.
29. Monahan, B.P.; Ferguson, C.L.; Killeavy, E.S.; Lloyd, B.K.; Troy, J.; Cantilena, L.R., Jr. Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 1990, 264 (21), 2788-2791.
30. Jurima-Romet, M.J.; Crawford, K.; Cyr, T.; Inaba, T. Terfenadine metabolism in human liver in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 1994, 22 (6), 849-857.
31. Herrlin, K.; Segerdahl, M.; Gustafsson, L.L.; Kalso, E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000, 356, 2069-2070.
32. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277, 321-332.
33. Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F.J.; Tsutsui, M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996, 26 (7), 681-693.
34. Hickman, D.; Wang, J.-P.; Wang, Y.; Unadkat, J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos. 1998, 26 (3), 207-215.
35. 14C] phenacetin o-deethylase activity in human liver microsomes. Drug Metab. Dispos. 1997, 25 (9), 1097-1100.
36. 14c]naproxen O-demethylase activity in human liver microsomes evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 1996, 24 (1), 126-136.
37. 14C]dextromethorophan. Anal. Biochem. 1994, 219, 309-320.
38. Crespi, C.L.; Pennman, B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv. Pharmacol. 1997, 43, 171-188.
39. Crespi, C.L.; Miller, V.P.; Pennman, B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 1997, 248, 188-190.
40. Moody, G.C.; Griffin, S.J.; Mather, A.N.; McGinnity, D.F.; Riley, R.J. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 1999, 29 (1), 53-75.
41. Chu, I.; Favreau, L.; Soares, T.; Lin, C.-C.; Normeir, A.A. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Commun. Mass Spectrom. 2000, 14, 207-214.
42. Yin, H.; Racha, J.; Li, S.-Y.; Olejnik, N.; Satoh, H.; Moore, D. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: Application in CYP inhibition evaluation. Xenobiotica 2000, 30 (2), 141-154.
43. Crespi, C.L. Higher throughput screening with human cytochromes P450. Curr. Opin. Drug Discov. Dev. 1999, 2 (1), 15-19.
44. Davit, B.; Reynolds, K.; Yuan, R.; Ajayi, F.; Conner, D.; Fadiran, E.; Gillespie, B.; Sahajwalla, C.; Huang, S.-M.; Lesko, L.J. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J. Clin. Pharm. 1999, 39, 899-910.
45. Guidance for Industry In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling, U.S. Department of Heath and Human Services, Food and Drug Administration, Center for Drug Evaluations and Research, November 1999.
46. Brackett, C.C.; Bloch, J.D. Phenytoin as a possible cause of acetaminophen hepatotoxicity: Case report and review of the literature. Pharmacotherapy 2000, 20 (2), 229-233.
47. Lin, J.H.; Lu, A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 1998, 35 (5), 361-390.
48. Kocarek, T.A.; Schuetz, E.G.; Strom, S.C.; Fisher, R.A.; Guzelian, P.S. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 1995, 23 (3), 415-421.
49. Lehman, J.M.; McKee, D.D.; Watson, M.A.; Willson, T.M.; Moore, J.T.; Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Investig. 1998, 102 (5), 1016-1023.
50. Jones, S.A.; Moore, L.A.; Shenk, J.L.; Wisely, G.B.; Hamilton, G.A.; McKee, D.D.; Tomkinson, N.C.O.; LeCluyse, E.L.; Lambert, M.H.; Willson, T.M.; Kliewer, S.A.; Moore, J.T. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 2000, 14, 27-39.
51. Collins, J.M. Regulatory viewpoint: Prediction of drug interactions from in vitro studies. In Metabolic Drug Interactions; Levy, R.H., Thummel, K.E., Trager, W.F., Hansten, P.D., Eichelbaum, M., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2000; 41-47.
52. Mutlib, A.E.; Chen, H.; Nemeth, G.A.; Markwalder, J.A.; Seitz, S.P.; Gan, L.S.; Christ, D.D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz. Drug Metab. Dispos. 1999, 27 (11), 1319-1333.